Next Article in Journal
Terpenoids and Phenylpropanoids in Ligularia duciformis, L. kongkalingensis, L. nelumbifolia, and L. limprichtii
Next Article in Special Issue
Amikacin: Uses, Resistance, and Prospects for Inhibition
Previous Article in Journal
Drug-Target Interaction Prediction through Label Propagation with Linear Neighborhood Information
Open AccessArticle

Inhibition by Commercial Aminoglycosides of Human Connexin Hemichannels Expressed in Bacteria

1
Department of Cell Physiology and Molecular Biophysics, and Center for Membrane Protein Research, Texas Tech University Health Sciences Center, Lubbock, TX 79430-6551, USA
2
Honors College, McClellan Hall, Box 41017, Texas Tech University, Lubbock, TX 79409-1017, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2017, 22(12), 2063; https://doi.org/10.3390/molecules22122063
Received: 4 October 2017 / Revised: 21 November 2017 / Accepted: 23 November 2017 / Published: 25 November 2017
(This article belongs to the Special Issue Recent Development on the New Applications of Aminoglycosides)
In addition to gap junctional channels that mediate cell-to-cell communication, connexins form hemichannels that are present at the plasma membrane. Since hemichannels are permeable to small hydrophilic compounds, including metabolites and signaling molecules, their abnormal opening can cause or contribute to cell damage in disorders such as cardiac infarct, stroke, deafness, skin diseases, and cataracts. Therefore, hemichannels are potential pharmacological targets. A few aminoglycosides, well-known broad-spectrum antibiotics, have been shown to inhibit hemichannels. Here, we tested several commercially available aminoglycosides for inhibition of human connexin hemichannels using a cell-based bacterial growth complementation assay that we developed recently. We found that kanamycin A, kanamycin B, geneticin, neomycin, and paromomycin are effective inhibitors of hemichannels formed by connexins 26, 43, and 46 (Cx26, Cx43, and Cx46). Because of the >70 years of clinical experience with aminoglycosides and the fact that several of the aminoglycosides tested here have been used in humans, they are promising starting points for the development of effective connexin hemichannel inhibitors. View Full-Text
Keywords: gap junction; channel; Cx26; Cx43; Cx46; screening; LB2003; antibiotic; cell-based assay; transport gap junction; channel; Cx26; Cx43; Cx46; screening; LB2003; antibiotic; cell-based assay; transport
Show Figures

Figure 1

MDPI and ACS Style

Fiori, M.C.; Krishnan, S.; Kjellgren, A.; Cuello, L.G.; Altenberg, G.A. Inhibition by Commercial Aminoglycosides of Human Connexin Hemichannels Expressed in Bacteria. Molecules 2017, 22, 2063.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop